Biogen BIIB Rare Disease Product Revenue — Total Revenue

Other product segments

Similar metrics at other companies

ANIPRare Disease total net revenues — Net Revenues

$94.37M+36.9%

ANIPRare Disease and Brands total net revenues — Net Revenues

$128.24M+36.3%

ANIPRare Disease and Brands — Net Revenues

$128.24M+36.3%

HRMYRare Neurological Diseases — Revenue

$215.39M+16.6%

INSMTotal Revenue

$305.96M+230%

RYTMProduct revenue, net — Total revenues

$60.11M+59.4%

Questions, answered.

What is Biogen's rare disease product revenue — total revenue?

Biogen (BIIB) reported rare disease product revenue — total revenue of $557.2M in Q1 2026.

How has Biogen's rare disease product revenue — total revenue changed year-over-year?

Biogen's rare disease product revenue — total revenue decreased by 1.1% year-over-year, from $563.3M to $557.2M.

What is the long-term trend for Biogen's rare disease product revenue — total revenue?

Over 4 years (2021 to 2025), Biogen's rare disease product revenue — total revenue has grown at a 3.1% compound annual growth rate (CAGR), from $1.91B to $2.15B.

What does rare disease product revenue — total revenue mean?

This metric represents the total gross revenue generated from the sale of pharmaceutical products specifically indicated for the treatment of rare or orphan diseases. It reflects the company's commercial success in addressing niche therapeutic areas with high unmet medical needs and often premium pricing structures. This revenue stream is a critical indicator of the company's diversification strategy beyond its core multiple sclerosis portfolio.